ATARA BIOTHERAPEUTICS, INC. Diluted Shares Outstanding (Weighted Average)
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Diluted Shares Outstanding (Weighted Average) of 15.03 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 15.03M shares, a 22.12% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 14.08M shares, a 29.77% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 13.91M shares, a 29.93% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 13.56M shares, a 81.68% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2025 was 12.72M shares, a 69.85% increase from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2024 was 7.49M shares, a 76.77% increase from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2023 was 4.24M shares, a 95.85% decline from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2022 was 101.99M shares, a 8.88% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 12 month | Weighted Average Number of Shares Outstanding, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 15.03M shares 10-Q · filed 2026-08-12 | 14.56M shares 10-Q · filed 2026-08-12 | 14.34M shares derived: average of 3 quarters · filed 2026-08-12 | 14.15M shares derived: average of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | 14.08M shares 10-Q · filed 2026-05-12 | 14.00M shares derived: average of 2 quarters · filed 2026-05-12 | 13.85M shares derived: average of 3 quarters · filed 2026-05-12 | 13.47M shares derived: average of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | 13.91M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 13.74M shares derived: average of 2 quarters · filed 2026-03-16 | 13.26M shares derived: average of 3 quarters · filed 2026-08-12 | 12.72M shares 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | 13.56M shares 10-Q · filed 2025-11-12 | 12.94M shares derived: average of 2 quarters · filed 2026-08-12 | 12.32M shares 10-Q · filed 2025-11-12 | 11.86M shares derived: average of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | 12.31M shares 10-Q · filed 2026-08-12 | 11.58M shares 10-Q · filed 2026-08-12 | 11.29M shares derived: average of 3 quarters · filed 2026-08-12 | 10.33M shares derived: average of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | 10.85M shares 10-Q · filed 2026-05-12 | 10.78M shares derived: average of 2 quarters · filed 2026-05-12 | 9.68M shares derived: average of 3 quarters · filed 2026-05-12 | 8.79M shares derived: average of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | 10.71M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 9.09M shares derived: average of 2 quarters · filed 2026-03-16 | 8.11M shares derived: average of 3 quarters · filed 2026-03-16 | 7.49M shares 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | 7.47M shares 10-Q · filed 2025-11-12 | 6.80M shares derived: average of 2 quarters · filed 2025-11-12 | 6.41M shares 10-Q · filed 2025-11-12 | 5.89M shares derived: average of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | 6.14M shares 10-Q · filed 2025-08-11 | 5.88M shares 10-Q · filed 2025-08-11 | 5.36M shares derived: average of 3 quarters · filed 2025-08-11 | 5.09M shares derived: average of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | 5.62M shares 10-Q · filed 2025-05-15 | 140.59M shares 10-Q · filed 2024-05-09 | 4.97M shares derived: average of 2 quarters · filed 2025-05-15 | 4.73M shares derived: average of 3 quarters · filed 2025-05-15 | 4.60M shares derived: average of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | 4.32M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | 4.29M shares derived: average of 2 quarters · filed 2025-03-07 | 4.26M shares derived: average of 3 quarters · filed 2025-03-07 | 4.24M shares 10-K · filed 2025-03-07 | 105.91M shares 10-K · filed 2024-03-28 | |||
| 2023-09-30 | 4.26M shares 10-Q · filed 2024-11-12 | 106.40M shares 10-Q · filed 2023-11-01 | 4.23M shares derived: average of 2 quarters · filed 2024-11-12 | 4.21M shares 10-Q · filed 2024-11-12 | 105.16M shares 10-Q · filed 2023-11-01 | 53.90M shares derived: average of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | 4.20M shares 10-Q · filed 2024-08-12 | 105.09M shares 10-Q · filed 2023-08-08 | 4.18M shares 10-Q · filed 2024-08-12 | 104.53M shares 10-Q · filed 2023-08-08 | 70.45M shares derived: average of 3 quarters · filed 2024-08-12 | 78.45M shares derived: average of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | 103.97M shares 10-Q · filed 2024-05-09 | 103.58M shares derived: average of 2 quarters · filed 2024-05-09 | 103.19M shares derived: average of 3 quarters · filed 2024-05-09 | 102.86M shares derived: average of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | 103.19M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 102.81M shares derived: average of 2 quarters · filed 2024-03-28 | 102.49M shares derived: average of 3 quarters · filed 2024-03-28 | 101.99M shares 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | 102.42M shares 10-Q · filed 2023-11-01 | 102.14M shares derived: average of 2 quarters · filed 2023-11-01 | 101.59M shares 10-Q · filed 2023-11-01 | 100.62M shares derived: average of 4 quarters · filed 2023-11-01 | ||||
| 2022-06-30 | 101.87M shares 10-Q · filed 2023-08-08 | 101.17M shares 10-Q · filed 2023-08-08 | 100.01M shares derived: average of 3 quarters · filed 2023-08-08 | 98.41M shares derived: average of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | 100.73M shares 10-Q · filed 2023-05-08 | 99.09M shares derived: average of 2 quarters · filed 2023-05-08 | 97.26M shares derived: average of 3 quarters · filed 2023-05-08 | 95.98M shares derived: average of 4 quarters · filed 2023-05-08 | ||||
| 2021-12-31 | 97.45M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | 95.52M shares derived: average of 2 quarters · filed 2023-02-08 | 94.40M shares derived: average of 3 quarters · filed 2023-02-08 | 93.67M shares 10-K · filed 2023-02-08 | ||||
| 2021-09-30 | 93.60M shares 10-Q · filed 2022-11-08 | 92.88M shares derived: average of 2 quarters · filed 2022-11-08 | 92.41M shares 10-Q · filed 2022-11-08 | |||||
| 2021-06-30 | 92.15M shares 10-Q · filed 2022-08-08 | 91.81M shares 10-Q · filed 2022-08-08 | ||||||
| 2020-12-31 | 73.97M shares 10-K · filed 2023-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |